PHAXIAM THERAPEUTICS S.A.

Press Releases PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Market Closed - Euronext Paris Other stock markets 09:05:02 03/05/2024 pm IST			5-day change	1st Jan Change
2.875 ^EUR	-1.54%		-2.54%	-37.50%

15/04	Phaxiam initiates trial in infective endocarditis	CF
15/04	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus	15/04	GL
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)	05/04	GL
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update	20/03	GL
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market	11/03	GL
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market	21/02	GL
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market	21/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW